|
|
Blood, 1 March 2008, Vol. 111, No. 5, pp. 2685-2692.
Prepublished online as a Blood First Edition Paper on November 29, 2007; DOI 10.1182/blood-2006-12-062265.
Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia
Liguang Chen1,2,
Lang Huynh1,2,
John Apgar3,
Li Tang1,2,
Laura Rassenti1,2,
Arthur Weiss4, and
Thomas J. Kipps1,2
1 Moores UCSD Cancer Center, University of California, San Diego;
2 Chronic Lymphocytic Leukemia (CLL) Research Consortium, San Diego, CA;
3 Department of Cell Signaling Research, BD PharMingen, San Diego, CA; and
4 Department of Medicine, Howard Hughes Medical Institute, University of California, San Francisco
We transduced chronic lymphocytic leukemia (CLL) cells lacking ZAP-70 with vectors encoding ZAP-70 or various mutant forms of ZAP-70 and monitored the response of transduced CLL cells to treatment with F(ab)2 anti-IgM (anti-µ). CLL cells made to express ZAP-70, a kinase-defective ZAP-70 (ZAP-70-KA369), or a ZAP-70 unable to bind c-Cbl (ZAP-YF292) experienced greater intracellular calcium flux and had greater increases in the levels of phosphorylated p72Syk, B-cell linker protein (BLNK), and phospholipase C- , and greater activation of the Ig accessory molecule CD79b in response to treatment with anti-µ than did mock-transfected CLL cells lacking ZAP-70. Transfection of CLL cells with vectors encoding truncated forms of ZAP-70 revealed that the SH2 domain, but not the SH1 domain, was necessary to enhance intracellular calcium flux in response to treatment with anti-µ. We conclude that ZAP-70 most likely acts as an adapter protein that facilitates B-cell receptor (BCR) signaling in CLL cells independent of its tyrosine kinase activity or its ability to interact with c-Cbl.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Unveiling ZAP-70's plan B
- Amélie Montel-Hagen, Rita Vicente, and Naomi Taylor
Blood 2008 111: 2501-2502.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
T. J. Kipps
Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy
ASCO Educational Book,
January 1, 2009;
2009(1):
385 - 393.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Z. Rassenti, S. Jain, M. J. Keating, W. G. Wierda, M. R. Grever, J. C. Byrd, N. E. Kay, J. R. Brown, J. G. Gribben, D. S. Neuberg, et al.
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Blood,
September 1, 2008;
112(5):
1923 - 1930.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Kipps
Chronic Lymphocytic Leukemia: Prognostic Markers and Revised Criteria for Treatment and Response Assessment
ASCO Educational Book,
January 1, 2008;
2008(1):
286 - 290.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|